Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) was featured on the latest episode of The BioMedWire Podcast, where co-founder and executive co-chair Anthony Durkacz discussed the company’s lead drug candidate, Lucid-MS, and its commercial product unbuzzd. The company is focused on advancing innovative therapies and technologies for neurodegenerative and metabolic disorders.
Durkacz emphasized that Lucid-MS is being developed to address mobility loss associated with multiple sclerosis by targeting nerve damage, an area he believes remains unmet by currently available treatments. Multiple sclerosis affects millions worldwide, and current therapies often fail to prevent or reverse myelin degradation, the underlying mechanism of the disease. Lucid-MS, a patented new chemical entity, has shown promise in preclinical models by preventing and reversing myelin degradation.
Quantum BioPharma is preparing for its upcoming Phase 2 clinical trial for Lucid-MS, which will be the first study to evaluate the drug candidate in multiple sclerosis patients, following Phase 1 testing in healthy volunteers. The success of this trial could position Lucid-MS as a potential breakthrough in MS treatment.
In addition to its pipeline, Durkacz highlighted the commercial potential of unbuzzd, an over-the-counter product designed to accelerate blood alcohol metabolism. Unbuzzd is currently available in the U.S. market through Unbuzzd Wellness Inc., a company spun out from Quantum. Quantum retains a 19.84% ownership stake in Unbuzzd as of March 31, 2026, and is entitled to royalty payments of 7% of sales until cumulative payments reach $250 million, after which the royalty drops to 3% in perpetuity. Quantum also retains 100% of rights to develop similar products for pharmaceutical and medical uses.
The company’s dual focus on prescription drugs and consumer health products provides a diversified revenue stream. The growth of unbuzzd could generate significant royalty income, which would support further development of Lucid-MS and other pipeline assets. For more information, the full press release is available at https://ibn.fm/HURxt.
Quantum BioPharma is dedicated to building a portfolio of innovative assets and biotech solutions for challenging neurodegenerative and metabolic disorders and alcohol misuse disorders. The latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM.
This news story relied on content distributed by NewMediaWire. Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is Quantum BioPharma Highlights Lucid-MS and unbuzzd Growth Opportunities on BioMedWire Podcast.